{"prompt": "['abbvie', 'Rovalpituzumab Tesirine', 'M16-298 Protocol Amendment 4', 'EudraCT 2016-003503-64', 'Appendix F.', 'New York Heart Association Classification', 'Class I', 'Patients with no limitation of activities; they suffer no symptoms from ordinary activities.', 'Class II', 'Patients with slight, mild limitation of activity; they are comfortable with rest or with', 'mild exertion.', 'Class III', 'Patients with marked limitation of activity; they are comfortable only at rest.', 'Class IV', 'Patients who should be at complete rest, confined to bed or chair; any physical activity', 'brings on discomfort and symptoms occur at rest.', '129']['abbvie', 'Rovalpituzumab Tesirine', 'M16-298 Protocol Amendment 4', 'EudraCT 2016-003503-64', 'Appendix G.', 'Response Evaluation Criteria for Solid Tumors (RECIST) V 1.1 for', 'Tumor Response', 'Response criteria will be assessed using RECIST (version 1.1). 12', 'Changes in the', 'measurable lesions over the course of therapy must be evaluated using the criteria listed', 'below.', 'Measurability', 'Measurable Lesions Lesions accurately measured in at least one dimension with a', 'minimum size of:', 'Longest diameter > 10 mm (CT scan slice thickness no', 'greater than 5 mm)', '10 mm caliper measurement by clinical exam', 'Non-Measurable', 'All other lesions, including small lesions (longest diameter', 'Lesions', '< 10 mm) as well as truly non-measurable lesions. Lesions', 'considered truly non-measurable include: leptomeningeal', 'disease, ascites, pleural/pericardial effusion, inflammatory', 'breast disease, lymphangitic involvement of skin or lung and', 'also abdominal masses that are not confirmed and followed by', 'imaging techniques.', 'Measurable', 'To be considered pathologically enlarged and measurable, a', 'Malignant Lymph', 'lymph node must be > 15 mm in short axis when assessed by', 'Nodes', 'CT scan (CT scan slice thickness recommended to be no', 'greater than 5 mm). At baseline and in follow-up, only the', 'short axis will be measured and followed.', 'Non-Measurable', 'Pathological lymph nodes with > 10 to < 15 mm short axis.', 'Malignant Lymph', 'Nodes', 'Special', 'Bone lesions', 'Considerations', 'Lytic bone lesions or mixed lytic-blastic lesions, with', 'Regarding Lesion', 'identifiable soft tissue components, that can be evaluated by', 'Measurability', 'cross sectional imaging techniques such as MRI/CT can be', 'considered as measurable lesions if the soft tissue component', 'meets the definition of measurability described above.', '130']['abbvie', 'Rovalpituzumab Tesirine', 'M16-298 Protocol Amendment 4', 'EudraCT 2016-003503-64', 'Blastic bone lesions are non-measurable.', 'Cystic lesions', 'Lesions that meet the criteria for radiographically defined', 'simple cysts should not be considered as malignant lesions', '(neither measurable nor non measurable) since they are, by', 'definition, simple cysts.', \"'Cystic lesions' thought to represent cystic metastases can be\", 'considered as measurable lesions, if they meet the definition of', 'measurability described above.', 'However, if non-cystic lesions are present in the same patient,', 'these are preferred for selection as target lesions.', 'Lesions with prior local treatment', 'Tumor lesions situated in a previously irradiated area, or in an', 'area subjected to other loco-regional therapy, are usually not', 'considered measurable unless there has been demonstrated', 'progression in the lesion.', 'All measurements should be taken and recorded in metric notation, using calipers if', 'clinically assessed. All baseline evaluations should be performed as closely as possible to', 'the beginning of treatment and not more than 28 days before the beginning of the', 'treatment.', 'The same method of assessment and the same technique should be used to characterize', 'each identified and reported lesion at baseline and during follow-up.', 'Clinical lesions will only be considered measurable when they are superficial (e.g., skin', 'nodules and palpable lymph nodes) and > 10 mm diameter as assessed using calipers. For', 'the case of skin lesions, documentation by color photography including a ruler to estimate', 'the size of the lesion is recommended.', '131']\n\n###\n\n", "completion": "END"}